Mirador unveils a piece of pipeline with drug from Kira to rival troubled Tavneos
Mirador unveils a pipeline piece licensed from Kira to rival the troubled Tavneos.
Mirador Therapeutics
Private
Biotech developing precision immunology and inflammation medicines, with a pipeline piece licensed from Kira Pharmaceuticals targeting the Tavneos (C5aR) space.
Company Info
Upcoming Milestones & Key Dates
2027
Regulatory
IND filing for MDR-001
Clinical Development Pipeline
MDR-001 (Kira-licensed anti-C5aR)
Target: C5aRUndisclosed
Target: TBDUndisclosed
Target: TBDRecent News
Leadership Team
Mark Forman
Chief Executive Officer
Management Team
Executive Leadership
Scientific Founders
Scientific Advisory Board